News Prostate drug approved for use in non-metastatic cases The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.
News J&J gets quick approval for new next-gen prostate cancer dru... The FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread.
News J&J files next generation prostate cancer drug in Europe After having filed its new prostate cancer drug apalutamide with the FDA in October, Johnson & Johnson have now submitted the drug to Europe’s EMA.
News EU regulators back J&J's Zytiga in early prostate cancer use New use could give J&J drug edge over Pfizer's rival
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.